ReviewCurrent oncology (Toronto, Ont.)2023

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.

Yingying Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.